Compare Moderna, Inc. (MRNA) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PayPal Holdings, Inc. — how do they compare? Moderna, Inc. trades at $218.64 (market cap $78.65B), while PayPal Holdings, Inc. trades at $55.47 (market cap $47.07B). The key difference: Moderna, Inc. is the larger of the two by market cap, and PayPal Holdings, Inc. pays a 1.02% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and PayPal Holdings, Inc. for 106 Days on average.
| MRNA | PYPL | |
|---|---|---|
Market Cap | $78.65B | $47.07B |
Volume | 37,373,437 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $203.46 | $75.75 |
52-Week Low | $22.36 | $39.08 |
Typical Hold Time | 59 Days | 106 Days |
Enterprise Value | $74.80B | $49.21B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
PayPal (PYPL) trades at $55.47, up 0.95% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.4, net income margin of 14.36%, and consistent revenue growth from $33.17B in 2025 to $34.1B projected for 2026. Recent positive developments include a Meta partnership for AI-powered checkout and three consecutive quarterly earnings beats.
PYPL presents a compelling value opportunity with attractive valuation multiples and solid profitability, though investors face risks from checkout competition and slowing growth. Analyst consensus leans cautious with 60% hold ratings, but the $56.41 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
